Beck Mack & Oliver’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Beck Mack & Oliver’s Portfolio FRTX Stock Details FRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-4	Closed	-$5K	–	284
2016 Q1	$5K	Hold	4	–	–	﹤0.01%	275
2015 Q4	$5K	Hold	4	–	–	﹤0.01%	288
2015 Q3	$6K	Hold	4	–	–	﹤0.01%	319
2015 Q2	$8K	Hold	4	–	–	﹤0.01%	345
2015 Q1	$11K	Hold	4	–	–	﹤0.01%	361
2014 Q4	$13K	Hold	4	–	–	﹤0.01%	361
2014 Q3	$13K	Hold	4	–	–	﹤0.01%	364
2014 Q2	$15K	Hold	4	–	–	﹤0.01%	371
2014 Q1	$15K	Hold	4	–	–	﹤0.01%	356
2013 Q4	$14K	Hold	4	–	–	﹤0.01%	365
2013 Q3	$15K	Hold	4	–	–	﹤0.01%	352
2013 Q2	$38K	Buy	+4	New	+$44.3K	﹤0.01%	345

Other funds holding FRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

CAM

ClariVest Asset Management San Diego, California $980M AUM 60.89% 1-Year Est. Return

EGA

Eagle Global Advisors Houston, Texas $2.78B AUM 26.09% 1-Year Est. Return

Beck Mack & Oliver's FRTX Position: Q2 2016 in Review

Beck Mack & Oliver sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q2 2016, closing a stake of 4 shares — an estimated $5K sold.

Beck Mack & Oliver first reported a position in FRTX in Q2 2013 and held it in 12 quarters. The position peaked at $38K in Q2 2013. 36 funds tracked by Wall St. Rank hold FRTX as of Q2 2016.

Beck Mack & Oliver reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q2 2016 after selling out during the quarter.
Beck Mack & Oliver sold 4 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q2 2016, an estimated $5K.
Beck Mack & Oliver first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2013 and held it in 12 quarters.
Beck Mack & Oliver's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $38K in Q2 2013.
36 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q2 2016.

Based on Beck Mack & Oliver's 13F filing for Q2 2016, filed 29 Jul 2016.